Loading...
Market
Will Lirafugratinib be approved by FDA, EMA, or both by end of 2026?
2
Resolution / Starting Odds
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Official announcements from FDA, EMA, and other major health authorities
Story
Relay and Elevar Sign Licensing Deal for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma, Potentially Worth $500 Million
Dec 3, 2024, 01:04 PM
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for Lirafugratinib, a treatment aimed at FGFR2-driven cholangiocarcinoma and other solid tumors. Under the terms of the agreement, Relay Therapeutics is set to receive up to $500 million in total, which includes $75 million in upfront and regulatory milestone payments, as well as up to $425 million in potential commercial milestone payments and tiered royalties in the low-teens percentage range. This collaboration is expected to enhance Relay's oncology pipeline, particularly in addressing challenging cancer types.
View original story
Similar markets
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other regions • 25%
Not approved in any region • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
